Physician profile
Lynn P Wright
NPI 1346332137
$7,340.47
in general payments reported to CMS, 2019-2025
21 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $766 · 2021: $1,230 · 2022: $1,207 · 2023: $1,090 · 2024: $1,531 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,124.06 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $985.78 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $902.11 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $883.74 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $673.15 | 2019-2025 | Hetlioz, Fanapt |
| Abbvie INC. | $565.92 | 2021-2025 | Vraylar |
| Alkermes, INC. | $564.20 | 2019-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $480.23 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $425.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $144.50 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $115.79 | 2019-2024 | Rexulti |
| Amarin Pharma, INC. | $97.70 | 2020 | |
| Ironshore Pharmaceuticals INC. | $84.78 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $65.41 | 2022-2023 | Trintellix |
| Allergan, INC. | $55.16 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $47.13 | 2019 | |
| Axsome Therapeutics, INC. | $46.33 | 2024 | Auvelity |
| Neuronetics, INC. | $28.86 | 2019-2022 | |
| Celgene Corporation | $22.04 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.46 | 2023 | |
| Indivior INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.